Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Recurrence × Goserelin × Clear all

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 66 Breast Neoplasms 30 Neoplasms 5 Neoplasm Metastasis 4 Leiomyoma 2 Infertility 2 Breast Neoplasms, Male 2 Stage I Prostate Adenocarcinoma AJCC v7 1 Sexual Dysfunction, Physiological 1 Recurrence 1 Primary Dysautonomias 1 Patient Compliance 1 Ovarian Neoplasms 1 Osteoporosis 1 Osteitis Deformans 1 Lymphatic Metastasis 1 Kidney Diseases 1 Hypertension 1 Hyperlipidemias 1 Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1 Hereditary Sensory and Autonomic Neuropathies 1 Hemorrhage 1 Fallopian Tube Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Advanced Prostate Cancer 1 Advanced Metastatic Breast Cancer 1

Interventions

Cyclophosphamide 56 Dexamethasone 42 Lenalidomide 30 Peripheral Blood Stem Cell Transplantation 28 Rituximab 27 Filgrastim 25 Bortezomib 25 fludarabine phosphate 24 Carboplatin 22 Radiotherapy 21 Etoposide 21 Paclitaxel 19 Melphalan 19 Busulfan 18 Whole-Body Irradiation 17 Gemcitabine 17 Cytarabine 17 Cyclosporine 17 pomalidomide 16 Mycophenolic Acid 16 Bevacizumab 16 pembrolizumab 15 Cisplatin 15 fludarabine 14 Methotrexate 12 Calcium Dobesilate 12 venetoclax 11 Tacrolimus 11 Nivolumab 11 Bendamustine Hydrochloride 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00439751 2016-07-12

ELAAT

Ontario Clinical Oncology Group (OCOG)

Phase 3 Completed

Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡